Virology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Remdesivir prevents MERS coronavirus disease in monkeys

The experimental antiviral Remdesivir has successfully prevented disease in rhesus macaques infected with Middle East respiratory syndrome coronavirus ( MERS-CoV ), according to a new study from National Institutes of Health researchers.
Remdesivir prevented disease when administered before infection and improved the condition of macaques when given after the animals already were infected.

The new report from NIH’s National Institute of Allergy and Infectious Diseases ( NIAID ) was published in the Proceedings of the National Academy of Sciences ( PNAS ).

MERS-CoV is closely related to the 2019 novel coronavirus ( 2019-nCoV ) that has grown to be a global public health emergency since cases were first detected in Wuhan, China, in December.

Remdesivir has previously protected animals against a variety of viruses in lab experiments.
The drug has been shown experimentally to effectively treat monkeys infected with Ebola and Nipah viruses. Remdesivir also has been investigated as a treatment for Ebola virus disease in people.

The study involved three groups of animals: those treated with Remdesivir 24 hours before infection with MERS-CoV; those treated 12 hours after infection ( close to the peak time for MERS-CoV replication in these animals ); and untreated control animals.

The researchers observed the animals for six days. All control animals showed signs of respiratory disease.
Animals treated before infection fared well: no signs of respiratory disease, significantly lower levels of virus replication in the lungs compared to control animals, and no lung damage.
Animals treated after infection fared significantly better than the control animals: disease was less severe than in control animals, their lungs had lower levels of virus than the control animals, and the damage to the lungs was less severe.

The researchers have indicated that the promising study results support additional clinical trials of Remdesivir for MERS-CoV and 2019-nCoV.
At least two clinical trials of Remdesivir for 2019-nCoV are under way in China, and other patients with 2019-nCoV infection have received the drug under a compassionate use protocol.

MERS-CoV emerged in Saudi Arabia in 2012. Through December 2019, the World Health Organization ( WHO ) had confirmed 2,499 MERS-CoV cases and 861 deaths ( or about 1 in 3 ).
Because about one-third of MERS-CoV cases spread from infected people being treated in healthcare settings, the researchers suggest that Remdesivir could effectively prevent disease in other patients, contacts of patients, and healthcare workers.
They have also noted the drug might help patients who are diagnosed with MERS or 2019-nCoV if given soon after symptoms start.

Source: National Institutes of Health, 2020